Randomized phase III oncology trials: a survey and empirical Bayes inference
From MaRDI portal
Publication:2321782
Recommendations
- Bayesian Approaches to Randomized Trials
- The estimated and theoretical assurances and the probabilities of launching a phase III trial
- Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design
- A Bayesian Approach to the Design of Phase II Clinical Trials
- Handbook of statistics in clinical oncology
Cites work
- scientific article; zbMATH DE number 3124366 (Why is no real title available?)
- scientific article; zbMATH DE number 708500 (Why is no real title available?)
- Bayesian statistics and the efficiency and ethics of clinical trials
- Empirical Bayes deconvolution estimates
- Inference and missing data
- Optimal Rates of Convergence for Deconvolving a Density
- Parametric Empirical Bayes Inference: Theory and Applications
Cited in
(5)- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- The estimated and theoretical assurances and the probabilities of launching a phase III trial
- P-hacking in clinical trials and how incentives shape the distribution of results across phases
- A fiducial approach to the nonparametric deconvolution problem: the discrete case
This page was built for publication: Randomized phase III oncology trials: a survey and empirical Bayes inference
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2321782)